Navigation Links
Cempra, Inc. Announces Pricing of Its Initial Public Offering of Common Stock

CHAPEL HILL, N.C., Feb. 3, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced the pricing of its initial public offering of 8,400,000 shares of its common stock at a price to the public of $6.00 per share.  Cempra also has granted the underwriters a 30-day option to purchase up to an additional 1,260,000 shares to cover over-allotments, if any.

Shares of Cempra's common stock will trade on the NASDAQ Global Market under the symbol "CEMP" beginning on February 3, 2012. The closing of the offering is expected to occur on February 8, 2012, subject to the satisfaction of customary closing conditions. 

Stifel Nicolaus Weisel, Leerink Swann LLC and Cowen and Company, LLC are serving as joint book-running managers for the offering.  Needham & Company, LLC is acting as co-manager.

The offering of these securities will be made only by means of a prospectus.  A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission.  This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state. 

A copy of the prospectus relating to the offering may be obtained by contacting Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2720; Leerink Swann LLC, One Federal Street, 37th Floor, Boston, Massachusetts 02110, or by calling (800) 808-7525; or Cowen and Company, LLC c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, New York 11717, Attn: Prospectus Department, or by calling (631) 274-2806.  The final prospectus, when it is available, also may be obtained on the Securities and Exchange Commission's Web site at

About Cempra

Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates have both completed oral Phase 2 clinical trials and seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to utilize its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at


Robert E. Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226

Tony Russo, Ph.D.
Russo Partners, LLC
(212) 845-4251

Dr. Prabhavathi Fernandes
President and Chief Executive Officer
(919) 467-1716

SOURCE Cempra, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Webcast Alert: Heska Announces Fourth Quarter and Year-End 2011 Earnings Conference Call Webcast
2. Idenix Announces Removal of the Partial Clinical Hold on HCV Nucleotide Inhibitor, IDX184
3. CryoLife Announces Release Date and Teleconference Call Details for 2011 Fourth Quarter and Year End Financial Results
4. Perrigo Company Announces Quarterly Dividend
5. BioParadox Announces Partnership with Fogarty Institute for Innovation
6. Hybrid Fuels, Inc. Announces FDA Approved Lab Selection for Azul Instant™ - "Be Ready in an Instant"
7. Nautilus Neurosciences Announces New Patent Issued
8. Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe
9. Sapio Sciences Announces Exemplar Dx LIMS for Laboratories in the Burgeoning MDx Market
10. Medical Alarm to Begin Fulfillment of MediPendant™ Against Largest Purchase Order - Announces Additional Warrant Cancellations
11. RemedyMD Announces Investigate Cell Therapy, a Revolutionary Research Management System for Blood and Marrow Transplant Centers
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 Research and ... the "Membranes Market - Global Forecast to 2020" ... Asia-Pacific , accounting for 37.21% of the total ... Asia-Pacific region is projected to growth ... growth has been attributed primarily to the fast growing ...
(Date:11/25/2015)... 2015 --> ... Lizenz für das Patent über eine neue Hepatitis-B-Behandlung, welches ... innehaben, an Enyo Pharma vergeben haben. Im ... gerufenen und von Edelris gemeinsam mit seinen Partnern Inserm ... für HBV identifiziert, und es wurden neue Inhaltsstoffe entdeckt, ...
(Date:11/25/2015)... DUBLIN , November 25, 2015 ... has announced the addition of the  ... 2015-2019"  report to their offering.  ... announced the addition of the  "Global ...  report to their offering.  ...
Breaking Medicine Technology:
(Date:11/24/2015)... , ... November 24, 2015 , ... DMG Productions announced ... Begley Jr., airing first quarter 2016 via Discovery Channel. Dates and show times TBA. ... Province, and is in the business of producing and supplying medical marijuana pursuant to ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... LENR HHT Bolier Reactor System. Brillouin is the developer of renewable energy technologies ... low energy nuclear reactions (“LENR”), announced today that its WET™ and HHT™ Boiler ...
(Date:11/24/2015)... ... 2015 , ... American Family Care (AFC), the nation’s leading provider of urgent ... located in Metro Atlanta’s North Point Mall. The clinic is designed to test the ... is scheduled to operate through Dec. 24. , Holiday Pop-Up Clinic , Official Opening ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... been designated an Aetna Institute of Quality® Bariatric Surgery Facility for treating individuals ... and cost of health care services available to its members to help them ...
(Date:11/24/2015)... ... ... Bibliomotion is thrilled to announce the launch of UNCONVENTIONAL LEADERSHIP: ... Nancy M. Schlichting, Chief Executive Officer of Henry Ford Health System (November 24, ... patients and their families, shaped my desire to improve the system of care. I ...
Breaking Medicine News(10 mins):